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Atrial fibrillation is the most common cardiac arrhythmia seen in clinical practice, affecting 
more than 2 million Americans.1 Thromboembolic 
complications, specifically embolic stroke, is one of 
the most significant contributors to morbidity, mor-
tality, and cost associated with atrial fibrillation. 
The rate of stroke among patients with atrial fibrilla-
tion averages 5% per year, which is 2 to 7 times the 
rate for people without the disease.2 To reduce the 
risk of embolic stroke, lifelong anticoagulation is 
recommended with either warfarin or aspirin.
Although the use of antiarrhythmic agents has 
declined over the past few years, there is still a role 
for these agents in the management of selected 
patients with atrial fibrillation. Amiodarone, a class 
III antiarrhythmic drug, is often selected based on 
known safety in patients with reduced left ventricu-
lar function and relatively high level of effectiveness 
in preserving normal sinus rhythm.3-5
Unfortunately, amiodarone often complicates the 
use of warfarin in patients with atrial fibrillation. 
Amiodarone potentiates the pharmacodynamic 
response of warfarin by inhibiting metabolism 
through CYP 2C9. The combination of warfarin and 
amiodarone is considered a clinically significant 
drug interaction that can lead to prolongation of the 
international normalized ratio (INR) and potentially 
increased risk of hemorrhagic complications. The 
literature surrounding this drug interaction has 
focused primarily on initiation of amiodarone in 
patients on stable doses of warfarin.6-10 Based on this 
literature, empiric warfarin dose adjustment has 
been recommended when amiodarone is initiated in 
patients on stable doses of warfarin.
In clinical practice, amiodarone and warfarin 
are often initiated concurrently in patients with 
Amiodarone inhibits the metabolism of warfarin. Previous 
studies characterizing this drug interaction have focused on 
the effect of adding amiodarone to stable doses of warfarin. 
The objective of this study was to assess whether simultane-
ous initiation of warfarin and amiodarone results in early 
alteration of the international normalized ratio (INR) 
response to warfarin. Patients initiated on warfarin and 
amiodarone during the same hospitalization were included 
in the amiodarone (AMIO) group. Patients initiated on war-
farin alone (n = 42) were identified for the CONTROL group. 
The AMIO and CONTROL groups were matched based on 
age, gender, and ejection fraction <40% using propensity 
score matching (final n = 18 patients per group). Total and 
average daily warfarin dose was lower in the AMIO group, 
yet INR values were similar on each day between the 2 
groups. More patients in the AMIO group had an INR greater 
than 2 during the 5-day observation period as compared to 
the CONTROL group. In addition, there were trends toward 
greater deviation from INR values expected with a 5-mg daily 
warfarin dose among AMIO group patients. Simultaneous 
initiation of warfarin and amiodarone leads to an enhanced 
pharmacodynamic response to warfarin early in therapy. 
Although these data should be viewed as hypothesis generat-
ing, cautious dosing and monitoring with simultaneous ini-
tiation of warfarin and amiodarone may be warranted.
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new-onset atrial fibrillation. Due to the unique phar-
macokinetics and pharmacodynamics of both amio-
darone and warfarin, it is difficult to predict the 
onset of this significant drug interaction. In fact, 
because it can take several weeks or months to 
achieve steady state with amiodarone, it could be 
hypothesized that the onset of the amiodarone-war-
farin drug interaction could take several weeks or 
months as well. Therefore, it is unclear whether 
empiric warfarin dosage adjustment is necessary 
when warfarin and amiodarone are initiated con-
comitantly or whether the dose of warfarin should 
be reduced later in therapy. As such, management of 
this interaction is variable in clinical practice, and 
no standard of care exists.
In this study, we sought to better characterize the 
pharmacodynamic response to warfarin early in 
therapy when warfarin and amiodarone are initiated 
simultaneously.
METHODS
This study protocol was approved by the institu-
tional review board at Henry Ford Hospital, a 903-
bed urban teaching hospital located in Detroit, 
Michigan. Medical records from patients concomi-
tantly initiated on amiodarone and warfarin were 
retrospectively reviewed for patients admitted 
between January 1, 2005, and December 31, 2007. 
Patients who had orders for amiodarone loading 
doses of ≥600 mg/d on at least 4 of 5 days during the 
study period and warfarin processed on the same 
hospital day were evaluated for inclusion in the 
amiodarone (AMIO) group (n = 18). Patients who 
were initiated on warfarin alone between September 
2007 and April 2008 (n = 42) were evaluated for 
inclusion in the CONTROL group. The different date 
ranges were used for the 2 study groups due to avail-
ability of easily retrievable electronic data. CONTROL 
patient data were accessed through an electronic 
pharmacy anticoagulation monitoring system that 
did not become available until September 2007. The 
anticoagulation monitoring system was deemed 
more appropriate for identifying the control popula-
tion because it enabled simple identification of 
patients meeting inclusion and exclusion criteria 
without manual chart review. Given that patients 
eligible for inclusion in the AMIO group were fewer 
in number, a computerized system containing data 
prior to 2007 was required. Therefore, AMIO patient 
data were collected from an institutional medical 
record system, which reliably provided electronic 
data from January 1, 2005, to present. It should be 
noted that the primary source of data for both elec-
tronic systems used was the inpatient pharmacy 
computer system. The information contained in the 
systems is the same, but the ability to query data dif-
fers between the systems. Initial warfarin dose for all 
patients included in this analysis was 5 mg. Per hos-
pital policy, warfarin doses were administered each 
day at 21:00.
Patients were excluded from both study groups if 
they had received vitamin K within the past 7 days, 
had underlying hepatic disease affecting coagulopa-
thy (baseline INR >1.40), received warfarin prior to 
treatment with amiodarone, or were concomitantly 
using a drug known to have a highly probable inter-
action with warfarin. The following drugs were con-
sidered to have highly probable interactions with 
warfarin: ciprofloxacin, sulfamethoxazole, cotrimox-
azole, erythromycin, fluconazole, isoniazid, levo-
floxacin, metronidazole, moxifloxacin, miconazole, 
voriconazole, diltiazem, fenofibrate, propafenone, 
propranolol, sulfinpyrazole, piroxicam, phenylbuta-
zole, citalopram, entacapone, sertraline, griseofulvin, 
nafcillin, ribavirin, cholestyramine, rifampin, mesala-
mine, barbiturates, argatroban, and carbamazepine.11
Patient demographic characteristics, medical his-
tory, and inpatient drug therapy were evaluated. 
Warfarin dose, amiodarone dose/route of adminis-
tration, and INR values during the first 5 days of 
therapy were also recorded.
The CONTROL group (n = 42) was matched to the 
AMIO group (n = 18) in a 1:1 ratio using nearest 
neighbor propensity score matching. The match was 
designed to yield 2 groups of patients (18 patients 
per group) who were matched based on age, gender, 
and ejection fraction (EF) <40%. Matching was car-
ried out with the freely available R software and 
“Matchit” package (www.r-project.org). All compari-
sons were made between the matched groups.
Several comparisons were made between groups 
to characterize the onset of the amiodarone-warfarin 
drug interaction. Mean daily warfarin dose, mean 
daily INR, change in INR over the evaluation period, 
and percent of patients achieving an INR value ≥2 
during the observation period were all compared 
between groups.
As a surrogate measure of “unpredictable 
response” to warfarin, the percentage of patients 
exceeding the maximum INR value predicted by the 
Crowther nomogram for a daily warfarin dose of 5 
mg was compared between groups (deviation from 
the nomogram). The Crowther nomogram is a dosing 
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tool used during the initiation of warfarin.12 Based 
on an initial 5-mg dose of warfarin, this nomogram 
helps characterize a patient's pharmacodynamic 
response and provides guidance for dosage adjust-
ments. Deviation from the nomogram was defined as 
an INR greater than 1.5 on day 2 of therapy, an INR 
greater than 1.9 on day 3 of therapy, and an INR 
greater than 3 on day 4 or 5 of therapy. These INR 
limits were defined as a “deviation” because exceed-
ing these INR values suggests that the warfarin dose 
should be reduced to less than 5 mg. Rate of devia-
tion from the nomogram was compared between 
groups at any time during the observation period, as 
well as on each individual day of the observation 
period.
Statistical Analysis
Continuous data are presented as mean ± standard 
deviation, and categorical data are presented as per-
cent. Continuous data were compared between the 
AMIO and CONTROL groups with a Student t test. 
Fischer's exact test was used to compare categorical 
variables between groups. A log rank test was used 




After propensity score matching, the AMIO and 
CONTROL groups were mostly balanced with regard 
to baseline characteristics (Table I). Left ventricular 
ejection fraction (LVEF) was lower in the AMIO 
group (P = .017). This was due to a greater propor-
tion of AMIO group patients having systolic heart 
failure (P = .007). Baseline INR was also slightly dif-
ferent between groups (P = .006). All patients in the 
AMIO group were on anticoagulation secondary to 
atrial fibrillation. The indication for anticoagulation 
varied in the CONTROL group; however, most 
patients were being treated for venous thromboem-
bolism (88.9%). Patients in the AMIO group received 
approximately 1 g of amiodarone daily (Table I).
Warfarin Dose-Response Relationship
Number of days of warfarin observed in the study 
was similar between the AMIO (4.67 ± 0.59 days) 
and CONTROL (4.89 ± 0.32) groups (P = .172). Total 
warfarin dose over the evaluation period (27.6 ± 8.4 
mg vs 22.6 ± 5.0 mg; P = .037) and average daily 
warfarin dose (5.7 ± 1.7 mg vs 4.9 ± 0.91 mg; P = 
.084) were lower in the AMIO group.
Despite the administration of lower warfarin doses 
to patients in the AMIO group, INR values were 
slightly but nonsignificantly higher in the AMIO 
group on days 2 to 4 after initiation of warfarin. Both 
groups experienced a similar change in INR between 
days 1 and 5 (AMIO: +0.86 ± 0.76, CONTROL: +0.90 
± 0.90; P = .90). More patients in the AMIO group 
achieved an INR greater than 2 on each individual 
day of the evaluation period (Table II).
There was a trend for deviation from the Crowther 
nomogram to occur more frequently in the AMIO 
group (39%) than in the CONTROL group (17%; P = 
.264). Deviation was uncommon on days 2 to 4 
among the control patients, whereas deviation was 
more likely to occur on days 2 and 3 in the AMIO 
Table I Baseline Patient Characteristics
Variable AMIO Group (n = 18) CONTROL Group (n = 18) P Value
Age, y, mean ± SD 70.1 ± 11.4 68.2 ± 11.4 .633
Male, % 72.2 44.4 .091
Weight, kg, mean ± SD 88.7 ± 16.2 83.2 ± 16.1 .323
Left ventricular ejection fraction, %, mean ± SD 39.7 ± 18.7 53.5 ± 5.9 .017
Systolic heart failure, % 44.4 5.6 .007
Hypertension, % 94.4 77.8 .148
Coronary artery disease, % 77.8 61.1 .278
Valve disease, %a 16.7 5.6 .289
Baseline international normalized ratio, mean ± SD 1.22 ± 0.12 1.13 ± 0.90 .006
Warfarin days, n, mean ± SD 4.67 ± 0.59 4.89 ± 0.32 .172
Total AMIO dose, mg, mean ± SD 4777.8 ± 1432.2 — —
Daily AMIO dose, mg, mean ± SD 1040.7 ± 362.3 — —
a. Valve disease = moderate/severe disease as visualized by echocardiogram.
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group (Figure 1). There was a trend for higher daily 
doses of amiodarone among those who deviated from 
the Crowther nomogram (15.6 ± 6.6 mg/kg), as com-
pared with those who did not deviate (11.0 ± 3.5 mg/
kg; P = .077). There was also a trend toward a shorter 
mean time to deviation from the Crowther nomogram 
among AMIO patients (P = .086; Figure 2).
A post hoc analysis in which the 2 groups were 
analyzed in strata based on the presence or absence 
of systolic heart failure was also completed. In this 
analysis, similar trends were noted for any deviation 
from the Crowther nomogram among both patients 
with (AMIO: 37.5%, CONTROL: 0%; P = 1.00) and 
without (AMIO: 40.0%, CONTROL: 17.6%; P = .365) 
systolic heart failure. Similar to the overall popula-
tion, in the strata of patients without systolic heart 
failure, there were significantly more deviations 
from the Crowther nomogram on day 3 of therapy in 
the AMIO group (40.0% vs 5.9%; P = .047).
DISCUSSION
In this study, differences in pharmacodynamic 
response were noted within the first few days of ther-
apy between patients initiated on warfarin alone or 
warfarin plus amiodarone. Despite lower warfarin 
doses in the AMIO group, patients taking amiodarone 
achieved an INR greater than 2, more frequently. In 
addition, there were trends for deviation from the 
maximum INR value predicted by the Crowther nomo-
gram to occur more frequently in the AMIO group. 
Although none of these measures independently 
proves early onset of the warfarin-amiodarone drug 
interaction, collectively these findings suggest that 
there is at least some inhibition of warfarin metabolism 
by amiodarone within the first few days of therapy.
Table II International Normalized Ratio (INR) Values: AMIO Group vs CONTROL Group
Day Day 2a Day 3 Day 4           Day 5
AMIO Less than 2, % 100.0 66.7 44.4 33.3
2-3, % 0.0 22.2 50.0 61.1
Greater than 3, % 0.0 11.1 5.6 5.6
Any INR greater than 2, % 0.0 33.3 55.6 66.7
CONTROL Less than 2, % 94.4 94.4 83.3 66.7
2-3, % 0.0 0.00 11.1 16.7
Greater than 3, % 5.6 5.6 5.6 16.7
Any INR greater than 2, % 5.6 5.6 16.7 33.3
P valueb 1.00 .088 .035 .094
a. A total of 36 INR values were evaluated on each day except day 2. Only 34 INR values were available on this day.



























Figure 1. Deviation from the Crowther nomogram.
Figure 2. Time to nomogram deviation. Censored data reflect end 
of observation without any deviation from the nomogram.
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Previous literature evaluating the warfarin-amio-
darone drug interaction has focused on initiation of 
amiodarone in patients on a stable dose of warfa-
rin.6-8,13 As such, much of the focus of these reports 
has been on delayed alterations in warfarin pharma-
codynamics as a result of amiodarone initiation. 
Therefore, a major difference between previous lit-
erature and this study is that this study evaluates the 
impact of amiodarone on warfarin pharmacodynam-
ics in the first 5 days of initiation of both therapies.
A notable comparison between previous literature 
and the current study is the need for reduction in 
warfarin dosage. In the current study, warfarin dose 
was 18.1% lower in the first 5 days of concomitant 
warfarin and amiodarone administration. Warfarin 
dosage reduction ranged from 17.3% after 1 week of 
concomitant therapy in 1 study6 to approximately 
30% after 4 to 8 weeks of amiodarone in addition to 
warfarin therapy.7,8 Our data may suggest that the 
onset of the warfarin-amiodarone drug interaction is 
similar, regardless of whether amiodarone is added 
to stable warfarin dosage or if the 2 drugs are initi-
ated at the same time. These data also suggest that 
the early impact of amiodarone on warfarin pharma-
codynamics does not represent the full impact of 
this drug interaction that will manifest after weeks 
of therapy.
The pharmacodynamic response of patients in 
this study was compared to the response that would 
be expected when using the Crowther nomogram. 
The Crowther nomogram is a dosing tool that was 
originally described several years ago.12,14,15 The orig-
inal reports relating to this dosing tool demonstrated 
that the use of 10-mg “loading” doses of warfarin in 
the first few days of warfarin therapy results in less 
efficient achievement of target INR ranges when 
compared to the use of a 5-mg loading dose. These 
studies also suggested that administration of 10-mg 
loading doses results in earlier achievement of an 
INR greater than 2 but also greater risk of developing 
a supratherapeutic INR (greater than 3). Of note, use 
of a 10-mg loading dose affected factor II levels 
similarly to the use of a 5-mg loading dose. However, 
factor VII and protein C levels were more dramati-
cally lowered in the first few days of therapy with 
the 10-mg loading dose.
Comparisons of the current study data to these 
early reports yield interesting results. First, the 5-day 
pattern of more rapid change in INR is similar between 
the 10-mg group from previous literature14,15 and the 
AMIO group in the current study. In addition, the 
AMIO group in the current study achieved an INR 
greater than 2 more frequently than the CONTROL 
group over a 5-day period. This is also similar to 
observations with the 10-mg group in previously pub-
lished studies.14,15 Thus, these findings are consistent 
with the theory that inhibition of warfarin metabo-
lism by amiodarone begins early after concomitant 
therapy has begun and suggest that concomitant ini-
tiation of amiodarone with warfarin may simulate 
initiation with higher doses of warfarin. Although 
this study did not evaluate protein C, factor II, or fac-
tor VII levels, one may hypothesize that similar 
results could have occurred in the setting of con-
comitant initiation of warfarin with amiodarone.
Some limitations of this study should be men-
tioned. First, despite the use of propensity score 
matching, the occurrence of systolic heart failure 
differed between the AMIO and CONTROL groups. 
This is notable because patients with systolic heart 
failure could have an altered pharmacodynamic 
response to warfarin.16 Therefore, the higher rate of 
heart failure in the AMIO group could explain the 
lower warfarin dose requirement and greater INR 
response. However, it seems that this difference did 
not influence our results because the post hoc analy-
sis revealed similar influence of amiodarone on 
warfarin pharmacodynamics, regardless of heart 
failure status. Another potential limitation of these 
data is the short duration of the study. Although our 
intent was to identify early influence of amiodarone 
on warfarin pharmacodynamics, characterization of 
this drug interaction beyond 5 days would also be 
useful. Because previous literature has not addressed 
concomitant initiation of warfarin and amiodarone, 
as was evaluated in this study, the time course for 
the full impact of this drug interaction remains 
unclear. However, these data do suggest that at the 
very least, clinicians should anticipate the initial 
onset of this drug interaction in the first few days of 
therapy. It should also be noted that some of the 
analyses performed in this study were underpow-
ered due to the small patient sample available. 
Finally, our study is limited by the use of a surrogate 
endpoint (INR) to measure the influence of the ami-
odarone-warfarin drug interaction. Although INR is 
well established as a measure of both efficacy and 
safety, it would be useful to know whether concomi-
tant initiation of these 2 medications leads to altered 
clinical outcomes. This question is especially relevant 
in light of recent studies that demonstrate worsened 
clinical outcomes due to well-known pharmacokinetic/ 
pharmacodynamic drug interactions.17,18 However, 
this study could provide pilot data to justify work 
evaluating the impact of concomitant warfarin and 
amiodarone on clinical outcomes in the future.
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CONCLUSION
Simultaneous initiation of warfarin and amiodarone 
likely leads to early inhibition of warfarin metabo-
lism and an enhanced pharmacodynamic response 
to warfarin early in therapy. Although these data 
should be viewed as hypothesis generating, cautious 
dosing and monitoring with simultaneous initiation 
of warfarin and amiodarone may be warranted.
This paper was presented as a poster, “Initial Clinical Observa-
tions When Simultaneously Initiating Warfarin and Amiodarone,” 
at the American Society of Health System Pharmacists Midyear 
Clinical Meeting in Las Vegas, Nevada, on December 3, 2007. 
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